Please login to the form below

Not currently logged in
Email:
Password:

KRAS

This page shows the latest KRAS news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $507m cancer deal with Effector Therapeutics

Pfizer signs $507m cancer deal with Effector Therapeutics

This includes patients with any KRAS mutation, amplifications or fusions in HER2, ERBB3, FGFR1 or FGFR2 receptor tyrosine kinases.

Latest news

More from news
Approximately 5 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The questions being asked are, what does an individual’s mutational profile look like, and do we have a drug to treat it; ie, do they have EGFR mutations, KRAS or

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics